Lo-H

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lo-H

Quick Facts

Property Description
Active Ingredients Losartan Potassium, Hydrochlorothiazide
Form Oral Tablet (Film-Coated)
Pharmacological Class Angiotensin II Inhibitor with Thiazides
Common Use Management of High Blood Pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Lo-H?

Lo-H is a synthetic, fixed-dose combination product for oral administration, primarily classified within the comprehensive Antihypertensive therapeutic category. It is supplied as a tablet and is designated to manage sustained elevated blood pressure. This specific pharmaceutical classification of Angiotensin II Inhibitors with Thiazides integrates two distinct pharmacological mechanisms. The development of such a combination is clinically recognized for achieving effective blood pressure control in individuals whose condition requires more than a single agent.

Composition: The Losartan and Hydrochlorothiazide Components

The active ingredients in Lo-H are Losartan Potassium and Hydrochlorothiazide (HCTZ). Losartan is formally an Angiotensin II Receptor Blocker (ARB), characterized by its role in managing vascular tone. Hydrochlorothiazide is a Thiazide Diuretic, a class of medications that act as "water pills." This dual composition is foundational to the drug's purpose, ensuring that it addresses both the hormonal regulation of vascular tone and the management of circulating fluid volume. This specific combination is utilized for its effectiveness in hypertension management.

The Benefit of Dual-Mechanism Antihypertensive Action

The general purpose of Lo-H is the effective stabilization of hypertension through its synergistic dual-mechanism approach. The action of the ARB component helps facilitate smoother blood flow, while the diuretic component promotes fluid reduction by increasing the renal removal of unneeded salt and water from the body. This combined strategy, which simultaneously mitigates vascular resistance and decreases plasma volume, is frequently employed when a patient requires sustained, comprehensive management for persistently elevated blood pressure. Other common brands sharing this exact formulation include Hyzaar, confirming the therapeutic utility of the Losartan/HCTZ combination.

What side effects are possible with Lo-H?

Possible Side Effects and Safety Information

The safety profile of Lo-H is based on regulatory documentation that categorizes adverse reactions primarily by System Organ Class (SOC) and frequency, adhering to the International Council for Harmonisation (ICH) guidelines.

Common and Less Common Adverse Reactions

The most commonly reported adverse reactions often affect the Nervous System and Gastrointestinal systems. Reactions are typically categorized by frequency:

  • Common (1/100 to < 1/10): Includes reactions such as dizziness, which is frequently cited, fatigue, and general gastrointestinal disturbances like nausea and diarrhea.
  • Uncommon/Rare: Reactions with lower incidence but which are still documented include various skin rashes and musculoskeletal pain (e.g., back pain, muscle cramps).

Clinically Significant Adverse Reactions and Warnings

Official labeling emphasizes several Serious Adverse Reactions that necessitate immediate attention, including signs of severe allergic reactions (e.g., swelling of the face, lips, throat) and marked hypotension (low blood pressure), especially upon initiation of therapy. Regulatory documents impose warnings and precautions regarding:

  • Renal Function: Caution is advised, and monitoring may be necessary, particularly in patients with pre-existing renal impairment or conditions that predispose them to it.
  • Electrolyte Imbalances: The potential for clinically significant changes in serum electrolytes (e.g., low potassium or sodium) is documented and requires monitoring.
  • Contraindications: Use is contraindicated during pregnancy, as the drug can cause fetal harm or death, particularly during the second and third trimensters. It is also contraindicated in patients with known hypersensitivity to the drug substance or excipients.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Lo-H (Losartan/Hydrochlorothiazide) describes specific clinical manifestations and mandated emergency responses in the event of an overdose.

Overdosage is primarily characterized by the severe consequences of the two components. The most likely effect is profound hypotension (low blood pressure) and compensatory tachycardia (rapid heart rate) from the Losartan component, though bradycardia (slow heart rate) is also documented. Overdose from the Hydrochlorothiazide component is linked to excessive diuresis, resulting in volume depletion and critical electrolyte imbalances, such as hypokalemia and hyponatremia. Severe outcomes can include acute renal failure and life-threatening cardiac arrhythmias.


Required Emergency Actions

Domain Regulatory Statement
Antidote Availability No specific antidote is known.
Mandated Action Individuals must seek immediate medical attention or contact a poison control center if overdosage is suspected.
Supportive Treatment Treatment is symptomatic and supportive, aiming to restore fluid and electrolyte balance. Measures may include gastric lavage or the administration of activated charcoal.
Elimination Status Losartan is not removed by hemodialysis; the extent to which hydrochlorothiazide is removed has not been established.

Immediate medical care is required for all suspected overdose situations to manage the symptoms and monitor for severe effects.

Therapeutic Uses of Lo-H

Lo-H is commonly used to help manage conditions characterized by periods of heightened symptoms associated with systemic imbalance, primarily concerning the circulatory system. This therapeutic approach is applied in addressing a primary physiological stressor.

The medicine is considered relevant for easing symptoms related to heightened physiological activity. It is commonly used for managing conditions such as high blood pressure and diabetic kidney disease.

Quick Fact: Relief for Heightened Physiological Activity

This effect assists with maintaining functional stability. Clinical contexts often involve acute or unstable symptom patterns where supportive symptom management is appropriate. By reducing the overall physiological strain, it contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods. The treatment supports patients during episodes of heightened discomfort. This supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lo-H?

Eligibility for using Lo-H (Losartan/Hydrochlorothiazide) is strictly defined by regulatory documents, focusing on patient population, age, and pre-existing conditions.

Approved and Restricted Populations

Lo-H is approved for use in adults with hypertension, particularly those whose blood pressure is not adequately controlled by a single agent. The combination product is not recommended for use in children and adolescents under 18 years because its safety and effectiveness have not been established in this age group.

Absolute Contraindications

Use of Lo-H is contraindicated (absolutely prohibited) for several groups:

  • Patients with documented hypersensitivity to Losartan, Hydrochlorothiazide, or any sulfonamide-derived drug.
  • Individuals with anuria or severe renal impairment (creatinine clearance leq 30 mL/min).
  • Patients with severe hepatic impairment, cholestasis, or biliary obstructive disorders.
  • Women who are in their second or third trimester of pregnancy.
  • Patients with diabetes who are taking medicines containing aliskiren.

Conditional Use

Lo-H should be used with caution in patients with mild to moderate hepatic impairment, and any pre-existing volume or salt depletion must be corrected prior to initiation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Losartan Potassium/Hydrochlorothiazide (Lo-H) is defined by official regulatory documents through specific restrictions, prohibitions, and conditions for co-administration.

Official Interaction Statements

Classification Interacting Agents & Restrictions
Contraindicated Combinations Co-administration with Aliskiren is prohibited in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m^2) due to the documented risk of hypotension, hyperkalemia, and decreased renal function.
Pharmacodynamic Risks Use with Lithium is not recommended because the combination reduces Lithium's renal clearance, increasing the risk of toxicity. Concomitant use with Potassium-Sparing Diuretics or Potassium Supplements is also restricted due to the heightened risk of hyperkalemia.
Exposure Alterations Fluconazole is documented to increase Losartan plasma exposure while reducing the exposure of its active metabolite. Conversely, Rifampin reduces the exposure of both Losartan and its active metabolite.
Timing Requirements Cholestyramine and Colestipol resins interfere with the absorption of the Hydrochlorothiazide component. Administration must be separated, with the drug taken at least 4 hours before or 4 to 6 hours after the resin.

General Interaction Context

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the antihypertensive effect and increase the risk of renal deterioration. The HCTZ component may impair glucose tolerance, requiring evaluation when used with antidiabetic drugs. The official labeling notes that Lo-H may be administered with or without food, and concurrent use of alcohol may potentiate orthostatic hypotension.

Mechanism of Action

The pharmacological action of Lo-H involves dual-component modulation of cardiovascular and renal physiology. The losartan component functions as a selective, competitive antagonist at the Angiotensin II type 1 (AT1) receptor. By binding to the AT1 receptor in tissues such as vascular smooth muscle and the adrenal gland, losartan and its active metabolite prevent the binding of Angiotensin II. This inhibition blocks the Gq protein-coupled pathway that typically mediates vasoconstriction, cellular proliferation, and aldosterone secretion. The resulting reduction in intracellular calcium flux in vascular myocytes leads to decreased peripheral vascular resistance. The second component, hydrochlorothiazide, is a thiazide diuretic that acts by inhibiting the Na^+-Cl^- cotransporter in the distal convoluted tubule of the nephron. This blockade decreases the reabsorption of sodium and chloride ions, consequently augmenting the osmotic movement of water into the tubule lumen. The resulting increase in urinary volume and electrolyte excretion diminishes plasma and extracellular fluid volume. System-level physiological consequences include combined peripheral vasodilation and reduced circulating fluid volume, resulting in modulation of systemic blood pressure.

Dosage and Administration Information

How Lo-H is Used: General Administration Guidelines

The administration of Lo-H, a fixed-dose combination product containing Losartan Potassium and Hydrochlorothiazide (HCTZ), follows established protocols. The medicine is designated for oral use as a film-coated tablet, which is to be swallowed whole with water. It is typically taken once daily, with or without food.

Dosing and Scheduling

The combination product is generally not intended for initial therapy; its use is reserved for adult patients whose blood pressure is not adequately controlled by monotherapy with either Losartan or HCTZ alone. The usual starting dose for most patients is the 50 mg/12.5 mg strength, taken once daily. The dose can be titrated, if needed, up to the maximum recommended daily dose of 100 mg/25 mg, but adjustments are typically considered only after three to four weeks of therapy, once the full antihypertensive effect is assessed.

Administration Constraints

Specific conditions for use apply to this medication. Prior to starting the medicine, any existing volume or sodium depletion must be corrected. Furthermore, the combination is not recommended for use in children and adolescents under 18 years. The combination is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or severe hepatic impairment. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped.

Recent Clinical Evidence

Recent Clinical Evidence / Overview of Studies

Phase I Trials: Initial Responses

Phase I studies investigated initial participant responses and how the drug was processed by the body in healthy volunteers. These early studies focused on identifying dose parameters for further clinical development. Studies also included participants with mild kidney impairment to assess the drug's profile in this group.


Phase II Trials: Early Data and Dose Exploration

Phase II research explored potential outcomes in specific patient populations. These trials focused on studying participant responses across different doses to inform later studies.

Research evaluated whether the combination was associated with changes in mobility and sleep patterns. Phase II data evaluated whether a higher dose was associated with greater changes in outcomes when managing acute episodes.


Phase III Trials: Profile and Long-Term Data

A large Phase III Randomized Controlled Trial (RCT) investigated the drug's effect on quality of life in individuals with chronic neuropathic pain. This study examined the drug's profile compared to a placebo over a three-month period. A large Phase III RCT demonstrated a measured change in pain scores over a 12-week period.

Studies have explored the onset and degree of changes in symptoms when compared to other treatments.


Research Investigating Cellular Pathways

Studies investigated specific actions of the study drug. Research explored potential correlations between the drug's actions and participant-reported changes in symptoms.

Key Studies & References Pharmacokinetics and Safety Profile of Lo-H in Healthy Volunteers and Subjects with Mild Renal Impairment (Phase I Study)

Frequently Asked Questions (FAQ)

Common questions about Lo-H (FAQ)

Q: How quickly should I expect to notice any effects from Lo-H?

A: According to official product information, the hydrochlorothiazide component may begin to act within 2 hours of taking the medicine. For the losartan component, a significant blood pressure-lowering effect is generally present within one week, but the maximum effect can take between 3 to 6 weeks to fully develop.

Q: Does Lo-H interact with common over-the-counter pain relievers?

A: Regulatory documents indicate that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may interact with Lo-H, potentially reducing its intended effect and increasing the risk of kidney function issues. Other common non-NSAID pain relievers are not specifically listed as documented interacting agents in the official prescribing information.

Q: Can seniors use Lo-H safely?

A: Official guidance indicates that dosage adjustments are generally not necessary for the elderly population. However, official guidance advises that certain older patients may require monitoring due to a potentially increased risk of specific side effects, such as electrolyte changes.

Q: Does Lo-H require any special lab tests or monitoring?

A: Regulatory documents advise that laboratory monitoring may be necessary during treatment. This monitoring is particularly focused on serum electrolytes (substances like potassium and sodium) and renal function (kidney function), due to the way the medicine works in the body.

Q: Why do some people experience mild dizziness with Lo-H?

A: Dizziness is a common side effect reported in clinical studies. Official labeling notes that the medicine can sometimes cause low blood pressure, known as hypotension, and dizziness is a common symptom associated with this decrease in blood pressure.

Q: Is it necessary to take Lo-H at the exact same time every day?

A: Official product information emphasizes that the medicine is administered once daily. Taking the medicine at a consistent time each day can help maintain continuous blood pressure management.

Q: What should I do if a side effect seems serious?

A: Official product labeling highlights that signs of a severe allergic reaction (such as swelling of the face, lips, or throat) are considered serious adverse events that warrant seeking immediate emergency medical attention. Guidance for symptoms of low blood pressure (hypotension) often suggests measures such as lying down and contacting a healthcare professional.

Q: Why is Lo-H sometimes preferred over older treatments?

A: The combination is recognized for providing a dual-mechanism approach to blood pressure control. The losartan component belongs to a class of medicines often associated with a lower rate of a dry cough compared to older classes of blood pressure medicines.

Q: What were the results of the key clinical trials for Lo-H?

A: Studies and official information indicate that for patients who have high blood pressure and left ventricular hypertrophy (LVH), the medicine can reduce the risk of stroke.

Q: Is Lo-H used for conditions other than the main described use?

A: The drug is officially indicated for the treatment of high blood pressure (hypertension). It is also approved for reducing the risk of stroke in patients who have high blood pressure and left ventricular hypertrophy (LVH).

Q: How long does Lo-H stay in your system after stopping treatment?

A: The active ingredients are cleared from the body at different rates. The half-life for hydrochlorothiazide is 6 to 15 hours, and for the active losartan component, it is 6 to 9 hours. Due to these factors, elimination of the components is estimated to take several days.

Q: Can Lo-H cause weight gain or weight loss?

A: Weight gain or loss is not listed as a common adverse reaction in the official product labeling. However, sudden or unexplained weight changes are not listed as common and may be relevant to discuss with a healthcare professional.

Q: Does Lo-H affect sleep or cause insomnia?

A: Official adverse reaction data shows that insomnia (inability to sleep) and general sleep disorder have been reported as uncommon or rare side effects associated with the medicine.

Q: What ingredients are in Lo-H besides the active substance?

A: The official label lists the inactive ingredients, also called excipients, used to form the tablet. These generally include substances like lactose anhydrous, magnesium stearate, microcrystalline cellulose, and titanium dioxide.

Q: Is it okay to take vitamins or supplements alongside Lo-H?

A: Official labeling specifically warns about the heightened risk of hyperkalemia (high potassium) when the drug is taken with potassium-sparing diuretics or potassium supplements. General daily vitamins are not listed as documented interacting agents.

Q: Is Lo-H considered a controlled substance?

A: Lo-H (Losartan/Hydrochlorothiazide) is not classified as a controlled substance under the US Controlled Substances Act (CSA).

Q: Can Lo-H be taken while breastfeeding?

A: Use of Lo-H is generally not recommended while breastfeeding. Regulatory information indicates that a clinical decision must be made regarding whether to discontinue nursing or discontinue the medication, as the hydrochlorothiazide component is known to be excreted into human milk.

Q: Are there any specific warnings about driving or operating machinery while on Lo-H?

A: Because the medicine may cause side effects like dizziness, lightheadedness, or fainting, official warnings recommend assessing one's personal reaction to the drug before engaging in activities that require mental alertness.

Q: How does Lo-H affect mood or anxiety levels?

A: Official adverse reaction data includes reports of anxiety and depression as uncommon or rare side effects associated with the drug.

Q: Does the efficacy of Lo-H depend on diet or lifestyle?

A: Official information states the tablets can be taken with or without food. However, patients who are on a low-salt diet may have an increased risk of low blood pressure (hypotension) when starting the medicine, which is a known precaution.

Q: What is the duration of treatment generally recommended for Lo-H?

A: Lo-H is a medication approved for the management of high blood pressure, which is defined as a chronic condition. Treatment duration is typically indefinite and determined by the healthcare provider to ensure sustained blood pressure control.

Q: Is Lo-H intended for short-term or long-term use?

A: The medicine is approved for the management of high blood pressure, which is a chronic condition. Therefore, the drug is generally intended for long-term use rather than short-term administration.

How should Lo-H be stored and disposed of?

How to Store and Dispose of Lo-H?

Official Storage Requirements

Lo-H (Losartan Potassium and Hydrochlorothiazide) tablets must be stored at controlled room temperature, which is defined as 20 C to 25 C. It is essential to protect the medicine from moisture by keeping the container tightly closed in a dry environment. The storage location must ensure the product remains out of the sight and reach of children, as required for all prescription medications.

Disposal Instructions

To dispose of unused or expired Lo-H responsibly, official guidelines advise against flushing the medicine down a toilet or throwing it into household trash. The recommended method for disposal is to return the product through a local drug take-back program or a medication collection site as directed by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lo-H found in:

A-Z Index: